Literature DB >> 34007087

Antiviral activity of 1,2,4-triazole derivatives (microreview).

Nataliia V Simurova1, Olena I Maiboroda1.   

Abstract

The microreview summarizes data published since 2015 on the antiviral properties and synthesis of compounds containing the 1,2,4-triazole ring. © Springer Science+Business Media, LLC, part of Springer Nature 2021.

Entities:  

Year:  2021        PMID: 34007087      PMCID: PMC8118685          DOI: 10.1007/s10593-021-02919-1

Source DB:  PubMed          Journal:  Chem Heterocycl Compd (N Y)        ISSN: 0009-3122            Impact factor:   1.277


Introduction Today, 1,2,4-triazole derivatives are the preferred structural moieties in the development of new drugs with a wide range of pharmacological activity, as evidenced by several reviews.[1] This is due to the fact that the triazole ring can be considered a bioisostere of an amide, ester, or carboxyl groups.[2] Relatively low toxicity, good pharmacokinetic and pharmacodynamic properties of triazole, its resistance to metabolic degradation are another advantages. In recent years, against the background of the emergence of new viral infections and the lack of effective chemotherapeutic agents for their treatment, the number of studies on the antiviral properties of 1,2,4-triazole derivatives has significantly increased. In the presented review, we focused on current publications devoted to the study of the antiviral properties of compounds containing the 1,2,4-triazole ring. Isosteric analogs of known drugs, as well as new molecules, are considered. Analogs of ribavirin and doravirine Ribavirin has antiviral activity against RNA and DNA viruses (hepatitis C, influenza A and B, herpes type 1 and 2 viruses, etc.). The possibility of using this compound for the treatment of hantavirus, various hemorrhagic fevers, as well as coronavirus is currently being evaluated.[3] Various mechanisms of action of ribavirin have been proposed. This molecule is thought to have different effects on different viruses. According to one hypothesis, ribavirin is an imitator of the purine guanosine cycle.[4] Zhurilo et al.[5] proposed two methods for the synthesis of ribavirin analogs 1 (chemical and chemoenzymatic methods starting from natural nucleoside substrates) by replacing the carboxamide fragment with the isostere 1,2,4-oxadiazole ring. The obtained compounds demonstrated high activity against viruses of hepatitis C, herpes simplex type 1, influenza A, comparable to the effect of ribavirin. Nataliia V. Simurova is Associate Professor at the Department of Food Chemistry of the National University of Food Technologies (Kyiv, Ukraine). She completed her PhD thesis in Chemical Sciences carried out under the guidance of Professor A. D. Sinitsa and defended it in 1995 at the Institute of Organic Chemistry of the National Academy of Sciences of Ukraine. Her research interests include chemistry of heterocyclic compounds, chemistry of trivalent phosphorus derivatives, and medicinal chemistry. Olena I. Maiboroda is Associate Professor at the Department of Food Chemistry of the National University of Food Technologies (Kyiv, Ukraine). She completed her PhD thesis in Chemical Sciences carried out under the guidance of Professor A. I. Tolmachev and defended it in 2002 at the Institute of Organic Chemistry of the National Academy of Sciences of Ukraine. Her scientific interests include synthesis of biologically active oxygen- and nitrogen-containing heterocyclic compounds, chemistry of polymethine dyes. Analogs of ribavirin and doravirine (continued) A series of studies by Chudinov et al.,[6] Tang et al.[7] is devoted to the synthesis of ribavirin analogs 2 containing a vinylaryl substituent at position 5 of the triazole ring. The relationship between the structure and activity of the obtained compounds E/Z-2 in regards to hepatitis C, influenza, and herpes simplex viruses was studied. The obtained results[6] indicate that all active compounds have common features: a rigid bond between the triazole and aryl rings, lipophilic substituents in the para position of the aryl ring. It was demonstrated that only the E-isomers possess high activity against herpes simplex virus comparable to the activity of ribavirin, while the Z-isomers are inactive. Wang et al.[8] synthesized a series of acetamide-substituted analogs of doravirine, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). Most of the obtained compounds 3 had inhibitory properties against HIV-1. Compound 3 with the 1,2,4-triazole substituent in the amide fragment showed excellent efficacy, comparable to that of doravirine and significantly superior to that of lamivudine, with high selectivity. Acyclovir isosteres Acyclovir is the ancestor of antiherpetic drugs – blockers of viral DNA synthesis. A series of isosteric analogs of acyclovir 4–8 containing the 1,2,4-triazole ring was obtained.[9] It was shown that derivatives substituted both at the endocyclic (compounds 4) and exocyclic (compound 5) nitrogen atoms are active against herpes simplex type 1 virus. Condensed triazolopyrimidines 8, which are structurally similar to purine bases, showed the highest activity with high selectivity and low toxicity. The authors of the study[9] believe that the lipophilicity of the substituents R1 and R2 is also an important factor determining the antiviral activity. As a result of physicochemical studies using the ADMET principle,[10] it was established that the closest analog of acyclovir, compound 8a, is a promising candidate for further development as an antiherpetic agent. It has also been shown9 that the replacement of the triazole ring with a thiadiazole one leads to the complete loss of antiviral activity. The introduction of the oxadiazole ring into compound 7 did not bring the desired result either. Substituted triazolethiones and thiols Recently, Zaher et al.[11] synthesized a number of 4-amino-5-hydrazine-4H-1,2,4-triazole-3-thiol derivatives 9, 10 while searching for effective inhibitors of the Nsp13 helicase of the MERS coronavirus. It was shown that the most active compounds are those containing halogen atoms in the para position of the aryl substituent and the cyclopentene fragment. Frączek et al.[12] synthesized a number of compounds 11, 12 based on 3,4-disubstituted triazole-5-thione. Compound 12 (R1 = Me, R2 = 4-carboxy-2-chlorophenyl, R3 = benzyl) showed high activity against HIV-1 and good pharmacokinetic properties. The authors believe that it may serve as the basis for the development of powerful new triazole NNRTIs for the treatment of HIV-1. A series of optically pure derivatives of 1,2,4-triazole-3-thiones 13 with a benzenesulfonamide group was synthesized by Başaran et al.[13] All compounds were tested for activity against a wide range of DNA and RNA viruses, including various strains of herpes simplex virus and HIV, as well as influenza A (H1N1, H3N2) and B viruses, varicella zoster virus, human cytomegalovirus, etc. It was demonstrated that enantiomers of 1,2,4-triazole-3-thiones of the R-configuration with electron-withdrawing substituents are potential candidates for the development of drugs against influenza A (H1N1) viruses, while the S-enantiomers do not exhibit antiviral activity. Condensed triazole derivatives Condensed 1,2,4-triazole derivatives possess a variety of biological activities, including antiviral activity, and therefore arouse considerable research interest. Stable σ-adducts of 1,2,4-triazolo[5,1-c]triazines and 1,2,4-triazolo-[1,5-a]-pyrimidines 14 with various polyphenols were obtained and their antiviral activity was investigated.[14] Triazoloazines modified with fluoroglycine have the greatest activity against influenza A (H1N1) virus. Molecular modeling has shown that their action is directed against viral hemagglutinin, a protein that ensures the ability of the virus to attach to the host cell.
  12 in total

1.  Isosteric ribavirin analogues: Synthesis and antiviral activities.

Authors:  Nikolay I Zhurilo; Mikhail V Chudinov; Andrey V Matveev; Olga S Smirnova; Irina D Konstantinova; Anatoly I Miroshnikov; Alexander N Prutkov; Lyubov E Grebenkina; Natalya V Pulkova; Vitaly I Shvets
Journal:  Bioorg Med Chem Lett       Date:  2017-11-15       Impact factor: 2.823

2.  Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Authors:  Tomasz Frączek; Agata Paneth; Rafał Kamiński; Agnieszka Krakowiak; Piotr Paneth
Journal:  J Enzyme Inhib Med Chem       Date:  2015-05-05       Impact factor: 5.051

3.  Pd-catalyzed oxidative C-H alkenylation for synthesizing arylvinyltriazole nucleosides.

Authors:  Jingjie Tang; Mei Cong; Yi Xia; Gilles Quéléver; Yuting Fan; Fanqi Qu; Ling Peng
Journal:  Org Biomol Chem       Date:  2015-01-07       Impact factor: 3.876

Review 4.  Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents.

Authors:  M Shaheer Malik; Saleh A Ahmed; Ismail I Althagafi; Mohammed Azam Ansari; Ahmed Kamal
Journal:  RSC Med Chem       Date:  2020-01-29

Review 5.  Bioactive nucleoside analogues possessing selected five-membered azaheterocyclic bases.

Authors:  Joanna Zeidler; Dagmara Baraniak; Tomasz Ostrowski
Journal:  Eur J Med Chem       Date:  2014-12-03       Impact factor: 6.514

6.  An alternative route to the arylvinyltriazole nucleosides.

Authors:  Mikhail V Chudinov; Alexander N Prutkov; Andrey V Matveev; Lyubov E Grebenkina; Irina D Konstantinova; Yulia V Berezovskaya
Journal:  Bioorg Med Chem Lett       Date:  2016-05-26       Impact factor: 2.823

7.  Synthesis of Novel Chiral Sulfonamide-Bearing 1,2,4-Triazole-3-thione Analogs Derived from D- and L-Phenylalanine Esters as Potential Anti-Influenza Agents.

Authors:  Eyüp Başaran; Ayşegül Karaküçük-Iyidoğan; Dominique Schols; Emine Elçin Oruç-Emre
Journal:  Chirality       Date:  2016-06       Impact factor: 2.437

8.  Synthesis, antioxidant, antifungal, molecular docking and ADMET studies of some thiazolyl hydrazones.

Authors:  Sushama Kauthale; Sunil Tekale; Manoj Damale; Jaiprakash Sangshetti; Rajendra Pawar
Journal:  Bioorg Med Chem Lett       Date:  2017-06-16       Impact factor: 2.823

9.  Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.

Authors:  Nashwa Hafez Zaher; Mohammed Ismail Mostafa; Abdullah Yousef Altaher
Journal:  Acta Pharm       Date:  2020-06-01       Impact factor: 2.230

Review 10.  Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.

Authors:  Jahan S Khalili; Hai Zhu; Nga Sze Amanda Mak; Yongqi Yan; Yi Zhu
Journal:  J Med Virol       Date:  2020-04-10       Impact factor: 2.327

View more
  2 in total

1.  The Synthesis of Triazolium Salts as Antifungal Agents: A Biological and In Silico Evaluation.

Authors:  Serghei Pogrebnoi; Oleg Radul; Eugenia Stingaci; Lucian Lupascu; Vladimir Valica; Livia Uncu; Anastasia Smetanscaia; Anthi Petrou; Ana Ćirić; Jasmina Glamočlija; Marina Soković; Athina Geronikaki; Fliur Z Macaev
Journal:  Antibiotics (Basel)       Date:  2022-04-27

2.  Expanding the chemical space of 3(5)-functionalized 1,2,4-triazoles.

Authors:  Dmytro M Khomenko; Roman O Doroshchuk; Yulia M Ohorodnik; Hanna V Ivanova; Borys V Zakharchenko; Ilona V Raspertova; Oleksandr V Vaschenko; Alexey V Dobrydnev; Oleksandr O Grygorenko; Rostyslav D Lampeka
Journal:  Chem Heterocycl Compd (N Y)       Date:  2022-03-23       Impact factor: 1.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.